{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:22:17Z","timestamp":1792624937386,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12026-025-09602-z","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T02:40:25Z","timestamp":1738896025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Killed whole-cell Staphylococcus aureus formulation in Montanide ISA266 and Alum adjuvants: different vaccine formulations varied in the vaccine\u2019s potency and efficacy"],"prefix":"10.1007","volume":"73","author":[{"given":"Mandana","family":"Bagherzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setareh","family":"Haghighat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Mahdavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"3","key":"9602_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SYC Tong","year":"2015","unstructured":"Tong SYC, et al. Staphylococcus aureus Infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603\u201361.","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"9602_CR2","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1172\/JCI18535","volume":"111","author":"FD Lowy","year":"2003","unstructured":"Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Investig. 2003;111(9):1265\u201373.","journal-title":"J Clin Investig"},{"issue":"2","key":"9602_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00281-011-0293-5","volume":"34","author":"B Spellberg","year":"2012","unstructured":"Spellberg B, Daum R. Development of a vaccine against Staphylococcus aureus. Seminars in Immunopathology. 2012;34(2):335\u201348.","journal-title":"Seminars in Immunopathology"},{"issue":"25","key":"9602_CR4","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1016\/j.vaccine.2013.04.002","volume":"31","author":"KU Jansen","year":"2013","unstructured":"Jansen KU, et al. Vaccine review: \u201cStaphyloccocus aureus vaccines: problems and prospects.\u201d Vaccine. 2013;31(25):2723\u201330.","journal-title":"Vaccine"},{"issue":"26","key":"9602_CR5","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1016\/j.vaccine.2016.03.110","volume":"34","author":"BK Giersing","year":"2016","unstructured":"Giersing BK, et al. Status of vaccine research and development of vaccines for Staphylococcus aureus. Vaccine. 2016;34(26):2962\u20136.","journal-title":"Vaccine"},{"key":"9602_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2021.104953","volume":"157","author":"Y Vahdani","year":"2021","unstructured":"Vahdani Y, et al. Molecular cloning and immunogenicity evaluation of IsdE protein of methicillin resistant Staphylococcus aureus as vaccine candidates. Microb Pathog. 2021;157: 104953.","journal-title":"Microb Pathog"},{"issue":"19","key":"9602_CR7","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1016\/j.vaccine.2011.11.006","volume":"30","author":"RA Proctor","year":"2012","unstructured":"Proctor RA. Is there a future for a Staphylococcus aureus vaccine? Vaccine. 2012;30(19):2921\u20137.","journal-title":"Vaccine"},{"issue":"1","key":"9602_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vaccine.2010.10.052","volume":"29","author":"MJ McConnell","year":"2010","unstructured":"McConnell MJ, Pach\u00f3n J. Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine. 2010;29(1):1\u20135.","journal-title":"Vaccine"},{"key":"9602_CR9","doi-asserted-by":"crossref","unstructured":"van Diemen PM, et al. Irradiated wild-type and Spa mutant Staphylococcus aureus induce anti- S. aureus immune responses in mice which do not protect against subsequent intravenous challenge. Pathog Dis. 2013;68(1):20\u201326.","DOI":"10.1111\/2049-632X.12042"},{"issue":"31","key":"9602_CR10","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1016\/j.vaccine.2017.05.085","volume":"35","author":"F Zhang","year":"2017","unstructured":"Zhang F, et al. Antibody-mediated protection against Staphylococcus aureus dermonecrosis and sepsis by a whole cell vaccine. Vaccine. 2017;35(31):3834\u201343.","journal-title":"Vaccine"},{"issue":"11","key":"9602_CR11","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/infdis\/jis579","volume":"206","author":"K Burnside","year":"2012","unstructured":"Burnside K, et al. Vaccination with a UV-irradiated genetically attenuated mutant of Staphylococcus aureus provides protection against subsequent systemic infection. J Infect Dis. 2012;206(11):1734\u201344.","journal-title":"J Infect Dis"},{"issue":"10","key":"9602_CR12","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1096\/fj.11-187963","volume":"25","author":"HK Kim","year":"2011","unstructured":"Kim HK, et al. Identifying protective antigens of Staphylococcus aureus, a pathogen that suppresses host immune responses. FASEB J. 2011;25(10):3605\u201312.","journal-title":"FASEB J"},{"issue":"2","key":"9602_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.vetmic.2010.10.003","volume":"148","author":"UP Pereira","year":"2011","unstructured":"Pereira UP, et al. Efficacy of Staphylococcus aureus vaccines for bovine mastitis: a systematic review. Vet Microbiol. 2011;148(2):117\u201324.","journal-title":"Vet Microbiol"},{"issue":"3","key":"9602_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.vetimm.2014.10.004","volume":"162","author":"CM Camussone","year":"2014","unstructured":"Camussone CM, et al. Immune response and functional role of antibodies raised in heifers against a Staphylococcus aureus CP5 lysate and recombinant antigens vaccine formulated with Iscom Matrix adjuvant. Vet Immunol Immunopathol. 2014;162(3):96\u2013107.","journal-title":"Vet Immunol Immunopathol"},{"issue":"1","key":"9602_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.rvsc.2013.10.004","volume":"96","author":"CM Camussone","year":"2014","unstructured":"Camussone CM, et al. Immune response of heifers against a Staphylococcus aureus CP5 whole cell and lysate vaccine formulated with ISCOM Matrix adjuvant. Res Vet Sci. 2014;96(1):86\u201394.","journal-title":"Res Vet Sci"},{"issue":"1","key":"9602_CR16","first-page":"56","volume":"69","author":"AA Badr","year":"2023","unstructured":"Badr AA, et al. Efficacy of lysigin vaccine in the prevention of mastitis in dairy cattle. Vet Med J (Giza). 2023;69(1):56\u201368.","journal-title":"Vet Med J (Giza)"},{"issue":"1","key":"9602_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1017\/S0022029905001354","volume":"73","author":"JR Middleton","year":"2006","unstructured":"Middleton JR, et al. Efficacy of different Lysigin\u2122 formulations in the prevention of Staphylococcus aureus intramammary infection in dairy heifers. J Dairy Res. 2006;73(1):10\u20139.","journal-title":"J Dairy Res"},{"key":"9602_CR18","doi-asserted-by":"crossref","unstructured":"Habibi M, Asadi Karam MR, Bouzari S. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model. Int Immunopharmacol. 2015;28(1):70\u201378.","DOI":"10.1016\/j.intimp.2015.05.027"},{"issue":"3","key":"9602_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1089\/vim.2021.0154","volume":"35","author":"Y Eshraghi","year":"2022","unstructured":"Eshraghi Y, et al. Immunomodulatory effects of \u03b1-tocopherol on the H1N1 influenza vaccine: improving the potency and efficacy of the influenza vaccine in aged mice. Viral Immunol. 2022;35(3):244\u201353.","journal-title":"Viral Immunol"},{"issue":"6","key":"9602_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1089\/vim.2023.0003","volume":"36","author":"A Sepasi","year":"2023","unstructured":"Sepasi A, et al. Formulation of recombinant H1N1 hemagglutinin in MF59 and alum adjuvants: a comparison of the vaccines potency and efficacy in BALB\/C mice. Viral Immunol. 2023;36(6):401\u20138.","journal-title":"Viral Immunol"},{"issue":"4","key":"9602_CR21","first-page":"292","volume":"12","author":"MA Savoji","year":"2019","unstructured":"Savoji MA, et al. Formulation of HBs antigen in Montanide ISA266 shows superiority to commercial HBsAg vaccine in the induction of humoral immune responses. Gastroenterol Hepatol Bed Bench. 2019;12(4):292\u2013300.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"issue":"3","key":"9602_CR22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbrc.2006.12.232","volume":"354","author":"F Roohvand","year":"2007","unstructured":"Roohvand F, et al. HCV core protein immunization with Montanide\/CpG elicits strong Th1\/Th2 and long-lived CTL responses. Biochem Biophys Res Commun. 2007;354(3):641\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"9602_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.molimm.2016.06.010","volume":"76","author":"M Shokri","year":"2016","unstructured":"Shokri M, et al. Comparing Montanide ISA 720 and 50\u2013V2 adjuvants formulated with LmSTI1 protein of Leishmania major indicated the potential cytokine patterns for induction of protective immune responses in BALB\/c mice. Mol Immunol. 2016;76:108\u201315.","journal-title":"Mol Immunol"},{"key":"9602_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.molimm.2016.12.013","volume":"82","author":"S Haghighat","year":"2017","unstructured":"Haghighat S, et al. Cloning, expression and purification of autolysin from methicillin-resistant Staphylococcus aureus: potency and challenge study in Balb\/c mice. Mol Immunol. 2017;82:10\u20138.","journal-title":"Mol Immunol"},{"key":"9602_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2023.106007","volume":"176","author":"M Dehnavi","year":"2023","unstructured":"Dehnavi M, et al. Glucomannan as a polysaccharide adjuvant improved immune responses against Staphylococcus aureus: potency and efficacy studies. Microb Pathog. 2023;176: 106007.","journal-title":"Microb Pathog"},{"issue":"1","key":"9602_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11274-022-03455-6","volume":"39","author":"A Ranjbariyan","year":"2022","unstructured":"Ranjbariyan A, et al. Synthetic selenium nanoparticles as co-adjuvant improved immune responses against methicillin-resistant Staphylococcus aureus. World J Microbiol Biotechnol. 2022;39(1):16.","journal-title":"World J Microbiol Biotechnol"},{"issue":"3","key":"9602_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s12026-024-09456-x","volume":"72","author":"M Mirshekar","year":"2024","unstructured":"Mirshekar M, et al. Monophosphoryl lipid A as a co-adjuvant in methicillin-resistant Staphylococcus aureus vaccine development: improvement of immune responses in a mouse model of infection. Immunol Res. 2024;72(3):490\u2013502.","journal-title":"Immunol Res."},{"key":"9602_CR28","doi-asserted-by":"publisher","first-page":"705360","DOI":"10.3389\/fimmu.2021.705360","volume":"12","author":"J Clegg","year":"2021","unstructured":"Clegg J, et al. Staphylococcus aureus vaccine research and development: the past, present and future, including novel therapeutic strategies. Front Immunol. 2021;12:705360\u2013705360.","journal-title":"Front Immunol"},{"key":"9602_CR29","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2147\/IDR.S175014","volume":"12","author":"S Ansari","year":"2019","unstructured":"Ansari S, et al. Recent advances in Staphylococcus aureus infection: focus on vaccine development. Infect Drug Resist. 2019;12:1243\u201355.","journal-title":"Infect Drug Resist"},{"key":"9602_CR30","doi-asserted-by":"crossref","unstructured":"van Diemen PM, et al. Irradiated wild-type and Spa mutant Staphylococcus aureus induce anti-S.\u00a0aureus immune responses in mice which do not protect against subsequent intravenous challenge. Pathog Dis. 2013;68(1):20\u20136.","DOI":"10.1111\/2049-632X.12042"},{"issue":"1","key":"9602_CR31","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1080\/21505594.2017.1417723","volume":"9","author":"M Moscoso","year":"2018","unstructured":"Moscoso M, et al. A D-Alanine auxotrophic live vaccine is effective against lethal infection caused by Staphylococcus aureus. Virulence. 2018;9(1):604\u201320.","journal-title":"Virulence"},{"issue":"4","key":"9602_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/1348-0421.12241","volume":"59","author":"GS Garcia-Romo","year":"2015","unstructured":"Garcia-Romo GS, et al. Immunization with heat-inactivated Staphylococcus aureus induced an antibody response mediated by IgG1 and IgG2 in patients with recurrent tonsillitis. Microbiol Immunol. 2015;59(4):193\u2013201.","journal-title":"Microbiol Immunol"},{"issue":"52","key":"9602_CR33","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.1016\/j.vaccine.2016.10.016","volume":"34","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, et al. Vaccine development: from concept to early clinical testing. Vaccine. 2016;34(52):6655\u201364.","journal-title":"Vaccine"},{"key":"9602_CR34","doi-asserted-by":"crossref","unstructured":"Luby CD, Middleton JR, Jianneng M, Rinehart CL, Bucklin S, Kohler C, Tyler JW. Characterization of the antibody isotype response in serum and milk of heifers vaccinated with a Staphylococcus aureus bacterin (Lysigin). J Dairy Res. 2007;74: 239\u201346.","DOI":"10.1017\/S0022029907002476"},{"issue":"2","key":"9602_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1089\/vim.2021.0143","volume":"35","author":"A Rezaei","year":"2022","unstructured":"Rezaei A, et al. Adjuvant effects of pseudomonas aeruginosa flagellin on the immunological patterns of the HIV-1 vaccine candidate: vaccine formulations versus different routes of immunization. Viral Immunol. 2022;35(2):150\u20138.","journal-title":"Viral Immunol"},{"issue":"10","key":"9602_CR36","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1089\/vim.2022.0022","volume":"35","author":"M Haghighi","year":"2022","unstructured":"Haghighi M, et al. Different formulations of inactivated SARS-CoV-2 vaccine candidates in human compatible adjuvants: potency studies in mice showed different platforms of immune responses. Viral Immunol. 2022;35(10):663\u201372.","journal-title":"Viral Immunol"},{"issue":"5","key":"9602_CR37","first-page":"779","volume":"138","author":"T Mohan","year":"2013","unstructured":"Mohan T, Verma P, Rao DN. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res. 2013;138(5):779\u201395.","journal-title":"Indian J Med Res"},{"key":"9602_CR38","doi-asserted-by":"crossref","unstructured":"Mortazavi SS, Haghighat S, Mahdavi M. Recombinant PBP2a of methicillin-resistant S. aureus formulation in Alum and Montanide ISA266 adjuvants induced cellular and humoral immune responses with protection in Balb\/C mice. Microbial Pathog. 2020;140:103945.","DOI":"10.1016\/j.micpath.2019.103945"},{"issue":"7","key":"9602_CR39","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1099\/jmm.0.038943-0","volume":"61","author":"M Kool","year":"2012","unstructured":"Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol. 2012;61(7):927\u201334.","journal-title":"J Med Microbiol"},{"issue":"21","key":"9602_CR40","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.3390\/ijms21218011","volume":"21","author":"X Zhu","year":"2020","unstructured":"Zhu X, Zhu J. CD4 T helper cell subsets and related human immunological disorders. Int J Mol Sci. 2020;21(21):8011.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"9602_CR41","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/ijms20092159","volume":"20","author":"S Kumar","year":"2019","unstructured":"Kumar S, et al. Dendritic cell-mediated Th2 immunity and immune disorders. Int J Mol Sci. 2019;20(9):2159.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9602_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1586\/14760584.1.1.111","volume":"1","author":"J Aucouturier","year":"2002","unstructured":"Aucouturier J, et al. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines. 2002;1(1):111\u20138.","journal-title":"Expert Rev Vaccines"},{"key":"9602_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107599","volume":"96","author":"MA Savoji","year":"2021","unstructured":"Savoji MA, et al. Formulation of HBsAg in Montanide ISA 51VG adjuvant: Immunogenicity study and monitoring long-lived humoral immune responses. Int Immunopharmacol. 2021;96: 107599.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"9602_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1017\/S0022029912000593","volume":"80","author":"CM Camussone","year":"2013","unstructured":"Camussone CM, et al. Immune response of heifers against a Staphylococcus aureus CP5 whole cell vaccine formulated with ISCOMATRIX\u2122 adjuvant. J Dairy Res. 2013;80(1):72\u201380.","journal-title":"J Dairy Res"},{"issue":"2\u20133","key":"9602_CR45","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3109\/08830185.2011.572210","volume":"30","author":"CL-L Chiang","year":"2011","unstructured":"Chiang CL-L, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol. 2011;30(2\u20133):150\u201382.","journal-title":"Int Rev Immunol"},{"issue":"10","key":"9602_CR46","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.4049\/jimmunol.1600883","volume":"197","author":"N Riteau","year":"2016","unstructured":"Riteau N, et al. Water-in-oil\u2013only adjuvants selectively promote T follicular helper cell polarization through a type I IFN and IL-6\u2013dependent pathway. J Immunol. 2016;197(10):3884\u201393.","journal-title":"J Immunol"},{"issue":"2","key":"9602_CR47","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1128\/IAI.66.2.451-461.1998","volume":"66","author":"LR Schopf","year":"1998","unstructured":"Schopf LR, et al. Interleukin-4-dependent immunoglobulin G1 isotype switch in the presence of a polarized antigen-specific Th1-cell response to the trypanosome variant surface glycoprotein. Infect Immun. 1998;66(2):451\u201361.","journal-title":"Infect Immun"},{"issue":"8","key":"9602_CR48","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.4049\/jimmunol.169.8.4298","volume":"169","author":"SG Tangye","year":"2002","unstructured":"Tangye SG, et al. Isotype switching by human B cells is division-associated and regulated by cytokines. J Immunol. 2002;169(8):4298\u2013306.","journal-title":"J Immunol"},{"issue":"4","key":"9602_CR49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0378-1135(02)00128-1","volume":"88","author":"N Avramidis","year":"2002","unstructured":"Avramidis N, et al. Adjuvant regulation of cytokine profile and antibody isotype of immune responses to Mycoplasma agalactiae in mice. Vet Microbiol. 2002;88(4):325\u201338.","journal-title":"Vet Microbiol"},{"issue":"4","key":"9602_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059786","volume":"8","author":"SI Jang","year":"2013","unstructured":"Jang SI, et al. Evaluation of Montanide\u2122 ISA 71 VG adjuvant during profilin vaccination against experimental coccidiosis. PLoS ONE. 2013;8(4): e59786.","journal-title":"PLoS ONE"},{"key":"9602_CR51","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.intimp.2018.01.035","volume":"56","author":"RZ Naghshbandi","year":"2018","unstructured":"Naghshbandi RZ, Haghighat S, Mahdavi M. Passive immunization against methicillin resistant Staphylococcus aureus recombinant PBP2a in sepsis model of mice: comparable results with antibiotic therapy. Int Immunopharmacol. 2018;56:186\u201392.","journal-title":"Int Immunopharmacol"},{"key":"9602_CR52","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-micro-041222-024605","volume":"78","author":"X Chen","year":"2024","unstructured":"Chen X, Missiakas D. Novel antibody-based protection\/therapeutics in Staphylococcus aureus. Ann Rev Microbiol. 2024;78:425\u201346.","journal-title":"Ann Rev Microbiol."},{"key":"9602_CR53","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3389\/fimmu.2020.01755","volume":"11","author":"I Bekeredjian-Ding","year":"2020","unstructured":"Bekeredjian-Ding I. Challenges for clinical development of vaccines for prevention of hospital-acquired bacterial infections. Front Immunol. 2020;11:1755.","journal-title":"Front Immunol"},{"key":"9602_CR54","doi-asserted-by":"crossref","unstructured":"Dubensky Jr TW, Reed SG. Adjuvants for cancer vaccines. In Seminars in immunology. 2010. Elsevier.","DOI":"10.1016\/j.smim.2010.04.007"},{"key":"9602_CR55","doi-asserted-by":"crossref","unstructured":"Nitcheu Tefit J, Serra V. Outlining novel cellular adjuvant products for therapeutic vaccines against cancer. Exp Rev Vaccines 2011;10(8):1207\u20131220.","DOI":"10.1586\/erv.11.84"},{"key":"9602_CR56","first-page":"97","volume-title":"Antigen delivery systems","author":"DE Stewart-Tull","year":"1998","unstructured":"Stewart-Tull DE. The choice and mechanism of action of adjuvants. In: Antigen delivery systems. CRC Press; 1998. p. 97\u2013121."},{"issue":"5","key":"9602_CR57","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","volume":"82","author":"N Petrovsky","year":"2004","unstructured":"Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488\u201396.","journal-title":"Immunol Cell Biol"},{"issue":"11","key":"9602_CR58","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","volume":"38","author":"N Petrovsky","year":"2015","unstructured":"Petrovsky N. Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug Saf. 2015;38(11):1059\u201374.","journal-title":"Drug Saf"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09602-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-025-09602-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09602-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:02:18Z","timestamp":1770192138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-025-09602-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9602"],"URL":"https:\/\/doi.org\/10.1007\/s12026-025-09602-z","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal study protocols were found to follow ethical principles, national norms, and standards for conducting Medical Research in Iran. The Islamic Azad Tehran Medical Sciences University-Pharmacy and Pharmaceutical Branches Faculty approved all experimental procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"47"}}